Literature DB >> 15364745

Intracoronary verapamil rapidly terminates reperfusion tachyarrhythmias in acute myocardial infarction.

Masaya Kato1, Keigo Dote, Shota Sasaki, Hiroaki Takemoto, Seiji Habara, Daiji Hasegawa.   

Abstract

BACKGROUND: The restoration of coronary flow after transient ischemia immediately induces life-threatening ventricular tachyarrhythmias. Although most of these arrhythmias disappear spontaneously, some of them induce serious hemodynamic changes. This retrospective study investigates the efficacy of therapy with intracoronary verapamil to terminate reperfusion-induced ventricular tachyarrhythmias in patients with acute myocardial infarction (AMI). METHODS AND
RESULTS: Between February 1992 and February 2003, 390 patients with a diagnosis of AMI were enrolled into the study. All patients received mechanical revascularization therapy within 6 h of onset of symptoms, and 109 patients experienced reperfusion-induced tachyarrhythmias. A subset of these patients was treated with intracoronary verapamil (0.25 to 1.0 mg) to terminate the reperfusion-induced tachyarrhythmia. They were evaluated for immediate termination of the tachyarrhythmias, hemodynamic changes, resumption rates, and major complications. Thirty-one patients (28%) were treated with intracoronary verapamil for the immediate termination of reperfusion-induced ventricular tachyarrhythmias. These tachyarrhythmias included 6 premature ventricular contractions, 19 accelerated idioventricular rhythms, 3 ventricular tachycardias, 2 ventricular fibrillations (VFs), and 1 torsades de pointes. Intracoronary verapamil was effective in rapidly terminating all reperfusion-induced arrhythmias except for VFs. The side effects of treatment included temporary hypotension (two patients) and bradycardia (one patient), although all patients recovered spontaneously. No major complications were induced by the intracoronary use of verapamil, and no resumptions of arrhythmias were documented.
CONCLUSION: Intracoronary administration of verapamil can safely terminate reperfusion-induced ventricular tachyarrhythmias in a rapid manner. However, this effect was not seen for reperfusion-induced VF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15364745     DOI: 10.1378/chest.126.3.702

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Activation of εPKC reduces reperfusion arrhythmias and improves recovery from ischemia: optical mapping of activation patterns in the isolated guinea-pig heart.

Authors:  Mark Restivo; Dmitry O Kozhevnikov; Yongxia S Qu; Yuankun Yue; Daria Mochly-Rosen; Nabil El-Sherif; Mohamed Boutjdir
Journal:  Biochem Biophys Res Commun       Date:  2012-08-22       Impact factor: 3.575

2.  Verapamil block of T-type calcium channels.

Authors:  Pamela Bergson; Gregory Lipkind; Steven P Lee; Mark-Eugene Duban; Dorothy A Hanck
Journal:  Mol Pharmacol       Date:  2010-12-13       Impact factor: 4.436

3.  Torsade de pointes as a reperfusion arrhythmia following intravenous thrombolytic therapy.

Authors:  Venkatesh Tekur
Journal:  J Cardiovasc Dis Res       Date:  2014-03-04

4.  Comparative effects of verapamil, nicardipine, and nitroglycerin on myocardial ischemia/reperfusion injury.

Authors:  Hitoshi Yui; Uno Imaizumi; Hisashi Beppu; Mitsuhiro Ito; Munetaka Furuya; Hirofumi Arisaka; Kazu-Ichi Yoshida
Journal:  Anesthesiol Res Pract       Date:  2011-03-02

Review 5.  ArrhythmoGenoPharmacoTherapy.

Authors:  Arpad Tosaki
Journal:  Front Pharmacol       Date:  2020-05-12       Impact factor: 5.810

6.  Antiarrhythmic calcium channel blocker verapamil inhibits trek currents in sympathetic neurons.

Authors:  S Herrera-Pérez; L Rueda-Ruzafa; A Campos-Ríos; D Fernández-Fernández; J A Lamas
Journal:  Front Pharmacol       Date:  2022-09-15       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.